Overall, our findings demonstrate the contribution of APLP2 as a potentiating factor in pancreatic cancer development and progression, and thus support future studies to evaluate APLP2 as a preventative or therapeutic target. This evidence concerns the gene APLP2 and pancreatic neoplasm.